Overview
- The company’s stock slid from about $151 in late May to roughly $68 during the week of July 20 as investors sold shares and rotated capital elsewhere.
- Rocket Lab announced an agreement to buy Iridium for about $8 billion and arranged mixed financing that includes sizeable bridge loans and an at-the-market equity program that heightened dilution worries.
- Insider selling, including sales by executives, and public questions about deal funding amplified market selling and prompted investor scrutiny.
- Operationally Rocket Lab reported record first-quarter revenue just above $200 million, a $2.2 billion backlog, and 31 new launch contracts, and it guided Q2 revenue toward a $240 million high with results due in early August.
- Near-term catalysts that will shape the outcome are clarity on financing terms and successful progress on key programs such as the Neutron rocket, with possible consequences for dilution, cash flow and shareholder value.